X免疫再構築症候群

文献

  1. French MA, Mallal SA, Dawkins RL. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunedeficient HIV-infected patients. AIDS. 6: 1293-1297, 1992.
  2. Lawn SD, Meintjes G. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther 9: 415-430, 2011.
  3. Dhasmana DJ, Dheda K, Ravn P, Wilkinson RJ, Meintjes G. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy. Drugs. 68:191-208, 2008.
  4. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother. 57: 167-170, 2006.
  5. Stoll M, Schmidt RE. Immune restoration inflammatory syndromes: The dark side of successful antiretroviral treatment. Curr Infect Dis Rep. 5: 266-276, 2003.
  6. Hoffmann CJ, Brown TT. Thyroid function abnormalities in HIV-infected patients. Clin Infect Dis. 47: 488-494, 2007.
  7. French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, Price P, Flexman JP, Tay-Kearney M-L. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Medicine. 1: 107-115, 2000.
  8. 古西 満,源河いくみ,中村哲也,善本英一郎,今村顕史,山元泰之,上平朝子,濱口元洋.免疫再構築症候群の臨床像に関する調査.厚生労働科学研究費補助金エイズ対策研究事業HAART時代の日和見合併症に関する研究平成16年度総括・分担研究報告書.84-92, 2005.
  9. Walker NF, Scriven J, Meintjes G, Wilkinson RJ. Immune reconstitution inflammatory syndrome in HIV-infected patients. HIV/AIDS-Research and Palliative Care. 7: 49-64, 2015
  10. Dutertre M, Cuzin L, Demonchy E, Puglièse P, Joly V, Valantin MA, Cotte L, Huleux T, Delobel P, Martin-Blondel G. Initiation of antiretroviral therapy containing integrase inhibitors increases the risk of IRIS requiring hospitalization. J Acquir Immune Defic Syndr. 76: e23-e26, 2017.
  11. Wijting IEA, Wit FWNM, Rokx C, Leyten EMS, Lowe SH, Brinkman K, Bierman WFW, Kasterren MEE, Postma AM, Bloemen VCM, Bouchtoubi G, Hoeoelman AIM, van der Ende ME, Reiss P, Rijnders BJA. Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy. EClinical Medicine 17, 2019. Doi: 10.1016/j.eclinm. 2019. 11. 003.
  12. Kityo C, Szubert AJ, Siika A, et al. Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomized controlled trial. PLoS Med 15, 2018. doi: 10.1371/journal.pmed.1002706.
  13. Müller M, Wandel S, Colubunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 10: 251-261, 2010.
  14. Sereti I, Sheikh V, Shaffer D, Phanuphak N, Gabriel E, Wang J, Nason MC, Roby G, Ngeno H, Kirui F, Pau A, Mican JM, Rupert A, Bishop R, Agan B, Chomchey N, Teeratakulpisarn N, Tansuphaswadikul S, Langat D, Kosgei J, French M, Ananworanich J, Sawe F. Prospective international study of incidence and predictors of immune reconstitution inflammatory syndrome and death in people living with human immunodeficiency virus and severe lymphopenia. Clin Infect Dis 2019. Doi: 10. 1093/cid/ciz877.
  15. 古西 満,照屋勝治,宇野健司,菱矢直邦,小川 拓,笠原 敬,三笠桂一.免疫再構築症候群の発症率・発症疾患に関する調査結果.第89回日本感染症学会西日本地方会学術集会・第62回日本感染症学会中日本地方会学術集会・第67回日本化学療法学会西日本支部総会プログラム・抄録集.218, 2019.
  16. Murdoch DM, Venter WDF, Van Rie A, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther. 4: 9, 2007.
  17. Lawn SD, Bekker L-G, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis. 5: 361-373, 2005.
  18. 小河原光正,坂谷光則,木村 剛.日和見疾患合併HIV感染症の多剤併用療法に関する研究.厚生労働科学研究費補助金エイズ対策研究事業多剤併用療法服薬の精神的、身体的負担軽減のための研究班平成17年度研究報告書.69-77,2006.
  19. Feller L, Wood NH, Lemmer J. Herpes zoster infection as an immune reconstitution inflammatory syndrome in HIV-seropositive subjects: a review. Surg Oral Med Oral Patho Oral Radiol Endod. 104: 455-460, 2007.
  20. 中村哲也,岡 慎一,永田洋一,蕪城俊克.CMV感染症における免疫再構築症候群の臨床的検討.厚生労働科学研究費補助金エイズ対策研究事業HAART時代の日和見合併症に関する研究平成16 年度総括・分担研究報告書.40-42,2005.
  21. Sungkanuparph S, Jongwutiwes U, Kiertiburanakul S. Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis. J Acquir Immune Defic Syndr. 45: 595-596, 2007.
  22. Miralles P, Berenguer J, Lacruz C, Cosín J, LóPez JC, Padilla B, Muñoz L, García-de-Viedma D. Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. AIDS. 15: 1900-1902, 2001.
  23. Pérez-Rueda M, Hernández-Cabrera M, Francés-Urmeneta A, Angel-Moreno A, Pisos-Álamo E, Jaén-Sánchez N, Carranza-Rodríguez C, Pérez-Arellano J-L. Immune reconstitution inflammatory syndrome in HIV-infected immigrants. Am J Trop Med Hyg 97: 1072-1077, 2017.
  24. Thambuchetty N, Mehta K, Arumugam K, Shekarappa UG, Idiculla J, Shet A. The epidemiology of IRIS in Southern India: An observational cohort study. J Int Assoc Provid AIDS Care 16: 475-480, 2017.
  25. 照屋勝治,田沼順子,立川夏夫.HIV感染者における免疫再構築症候群(サイトメガロウイルス網膜炎)発症予防に関する研究.厚生労働科学研究費補助金エイズ対策研究事業重篤な日和見感染症の早期発見と最適治療に関する研究平成19年度総括・分担研究報告書.34-38, 2008.
  26. 照屋勝治,岡 慎一,田沼順子,塚田訓久,佐野和美,青木孝弘.HIV感染者における免疫再構築症候群(サイトメガロウイルス網膜炎)発症予防に関する研究.厚生労働科学研究費補助金エイズ対策研究事業重篤な日和見感染症の早期発見と最適治療に関する研究平成20 年度総括・分担研究報告書.34-39, 2009.
  27. Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection: Clinical manifestations and treatment with steroids. Neurology. 72: 1458-1464, 2009.
  28. Kato H, Yanagisawa N, Morioka H, Sasaki S, Sekiya N, Suganuma A, Imamura A, Ajisawa A: laryngeal Kaposi sarcoma complicated by the immune reconstitution inflammatory syndrome in an HIV-infected patient. Intern Med. 55: 1001-1005, 2016.
  29. Zolopa AR, Andersen J, Komarow L, Sanne, Sanchez A, Hogg E, Suckow C, Powderly W. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: A multicenter randomized strategy trial. PLOS ONE. 4: e5575, 2009.
  30. Abay SM, Deribe K, Reda AA, Biadgilign S, Datiko D, Assefa T, Todd M, Deribew A. The effect of early initiation of antiretroviral therapy in TB/HIV-coinfected patients: A systematic review and meta-analysis. J Int Assoc Provid AIDS care. 14: 560-570, 2015.
  31. Makadzange AT, Ndhovu CE, Takarinda K, Reid M, Kurangwa M, Gona P, Hakim JG. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa. Clin Infect Dis. 50: 1532-1538, 2010.
  32. Boulware DR, Meya DB, Muzoora C, Rolfes MA, Hullsiek KH, Musubire A, Taseera K, Nabeta HW, Schutz C, Williams DA, Rajasingham R, Rhein J, Thienemann F, Lo MW, Nielsen K, Bergemann TL, Kambugu A, Manabe YC, Janoff EN, Bohjanen PR, Meintjes G. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med.370: 2487-2498, 2014.
  33. Eshun-Wilson I, Okwen MP, Richardson M, Bicanic T. Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis. Cochrane Database Syst Rev. 7: CD009012. Doi: 10. 2018.
  34. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents (米国DHHS, Feb.24, 2021). https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines
  35. Saag MS, Gandhi RT, Hoy JF, et al; Antiretroviral drugs for treatment and prevention of HIV infection in adults:2020 Recommendations of the international antiretroviral society-USA panel. JAMA. 324(16):1651-1669. 2020.
  36. 渡邉かおる,永井英明,河野史歩,加藤貴史,渡邉直昭,鈴木純子,松井弘稔,山根 章,田村厚久,赤川志のぶ,太田 健.HIV感染症合併結核患者における抗レトロウイルス療法開始時期と予後の検討.結核.92:623-628, 2017.
  37. Schäfer G, Hoffmann C, Arasteh K, Schürmann D, Stephan C, Jensen B, Stoll M, Bogner JR, Faetkenheuer G, Rockstroh J, Klinker H, Härter G, Stӧhr A, Degen O, Freiwald E, Hüfner A, Jordan S, Wiesch JS, Addo M, Lohse AW, Lunzen J, Schmiedel S. Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study). AIDS Res Ther 16, 2019. Doi: 10. 1186/s12981-019-0250-2.
  38. The TEMPRANO ANRS 12136 Study Group. A trial of early antiretroviral and isoniazid preventive therapy in Africa. N Engl J Med.373: 808-822, 2015.
  39. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med.373: 795-807, 2015.
  40. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-1-infected Adults and Adolescents (米国CDC, NIH, IDSA/HIVMA, Aug. 18, 2020 updated, Aug. 18, 2020 review). https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines
  41. Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, Ravinetto R, van Loen H, Nair A, Jackson A, Colebunders R, Maartens G, Wilkinson RJ, Lynen L. Prednisone for the prevention of paradoxical tuberculosis-associated IRIS. N Engl J Med. 379: 1915-1925, 2018.
  42. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis. 38: 1159-1166, 2004.
  43. Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX, Oni T, Maartens G. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 24: 2381-2390, 2010.
  44. Murthy AR, Marulappa R, Hegde U, Kappadi D, Ambikathanaya UK, Nair P. Treatment guidelines and prognosis of immune reconstitution inflammatory syndrome patients: A review. J Int Oral Health. 7: 92-95, 2015.
  45. Haddow LJ, Moosa M-YS, Mosam A, Moodley P, Parboosing R, Easterbrook PJ. Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa. PLosS ONE. 12 Nov 2012. Doi: org/10.1371/journal. pone. 0040623.
  46. Park WB, Choe PG, Jo JH, Kim S-H, Bang JH, Kim HB, Kim NJ, Oh M-d, Choe KW. Immune reconstitution inflammatory syndrome in the first year after HAART: influence on long-term clinical outcome. AIDS. 20: 2390-2392, 2006.

PAGE TOP

アンケートにご協力ください。

このページは役に立ちましたか?

コメント